Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: A case report

Journal of Hematology and Oncology

Volumn 2, Issue , 2009, Pages

  Malavasi, Norma ^a   Ponti, Giovanni ^a   Depenni, Roberta ^a   Bertolini, Federica ^a   Zironi, Sandra ^a   Luppi, Gabriele ^a   Conte, Pier Franco ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; FOLFOX PROTOCOL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ABDOMINAL PAIN; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CASE REPORT; CLINICAL ASSESSMENT; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; HEMICOLECTOMY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; POSITRON; PROGNOSIS; REVIEW; TREATMENT RESPONSE; ADENOCARCINOMA; ARTICLE; COLON TUMOR; LIVER TUMOR; METASTASIS; PATHOLOGY; REMISSION;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS; REMISSION INDUCTION;

EID: 69249230906     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-2-35     Document Type: Review

References (12)

1. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. TM Pawlik CR Scoggins D Zorzi EK Abdalla A Andres C Eng SA Curley EM Loyer A Muratore G Mentha L Capussotti JN Vauthey, Ann Surg 2005 241 715 722 10.1097/01.sla.0000160703.75808.7d 15849507 (Pubitemid 40604917)
2. Five-year survival following hepatic resection after neoadjuvant therapy for unresectable colorectal liver metastases. R Adam E Avisar A Ariche S Giachetti D Azoulay D Castaing F Kunstlinger F Levi F Bismuth, Ann Surg Oncol 2001 8 347 353 10.1007/s10434-001-0347-3 11352309
3. Resection of colorectal liver metastases. J Scheele R Stang A Altendorf-Hofmann M Paul, World J Surg 1995 19 59 71 10.1007/BF00316981 7740812
4. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. AA Parikh B Gentner TT Wu SA Curley LM Ellis JN Vauthey, J Gastrointest Surg 2003 7 1082 1088 10.1016/j.gassur.2003. 08.005 14675719 (Pubitemid 37526731)
5. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? R Adam G Pascal D Castaing D Azoulay V Delvart B Paule F Levi H Bismuth, Ann Surg 2004 240 1052 1064 10.1097/01.sla.0000145964.08365.01 15570210 (Pubitemid 39602132)
6. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. HM Kuerer LA Newman TL Smith FC Ames KK Hunt K Dhingra RL Theriault G Singh SM Binkley N Sneige TA Buchholz MI Ross MD McNeese AU Buzdar GN Hortobagyi SE Singletary, J Clin Oncol 1999 17 460 469 10080586
7. Prognostic value of Dworak grade regression (GR) in patients with rectal cancer treated with preoperative radiochemotherapy. L Losi G Luppi M Gavioli F Iachetta F Bertolini R D'Amico G Jovic F Bertoni AM Falchi PF Conte, Int J Colorectal Dis 2006 21 645 651 10.1007/s00384-005-0061-x 16317549 (Pubitemid 44446064)
8. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. DG Blazer 3rd Y Kishi DM Maru S Kopetz YS Chun MJ Overman D Fogelman C Eng DZ Chang H Wang D Zorzi D Ribero LM Ellis KY Glover RA Wolff SA Curley EK Abdalla JN Vauthey, J Clin Oncol 2008 25 5344 5351 10.1200/JCO.2008.17.5299
9. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality? R Adam DA Wicherts RJ de Haas T Aloia F Lévi B Paule C Guettier F Kunstlinger V Delvart D Azoulay D Castaing, J Clin Oncol 2008 26 1635 1641 10.1200/JCO.2007.13.7471 18375892
10. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? S Benoist A Brouquet C Penna C Julié M El Hajjam S Chagnon E Mitry P Rougier B Nordlinger, J Clin Oncol 2006 24 3939 3945 10.1200/JCO.2006.05.8727 16921046 (Pubitemid 46630742)
11. Surgery with curative intent in patients (pts) treated with first line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): first BEAT and NO16966. (Abstract). J Cassidy, Proc ASCO 2008
12. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal cancer liver metastases. D Ribero H Wang M Donadon D Zorzi MB Thomas C Eng DZ Chang SA Curley EK Abdalla LM Ellis JN Vauthey, Cancer 2007 110 2761 2767 10.1002/cncr.23099 17960603 (Pubitemid 350250347)